Lipella Pharmaceuticals
Pittsburgh, US · Delaware corporation
Lipella Pharmaceuticals was a clinical-stage biotechnology company that developed therapies using a proprietary liposomal drug delivery platform, advancing candidates such as LP-10 and LP-310 through FDA-authorized Phase 2 trials in indications including oral lichen planus and hemorrhagic cystitis. The company ceased research and development activities in 2026 after a court-approved sale of its drug programs and intellectual property to XRAIY LLC, and the site now serves as a historical corporate archive.
Founders & leadership
MC
Michael ChancellorChief Medical Officer
JK
Jonathan KaufmanCo-founder
DJ
Douglas JohnstonChief Financial Officer
Board
TP
THOMAS PETZINGER, JR.Board director
LB
Lori BirderBoard director
DC
Daniel CohenBoard director
NY
Naoki YoshimuraBoard director
RP
Ryan PruchnicBoard director
BK
Byong KimBoard director
DB
DAVID BATTLEMANBoard director
Reported raises · per SEC filings
Form D private placements$7.8M disclosed across 5 of 6 rounds · 2020–2025
▶$9KraisedApr 2025 · 29 investors · PharmaceuticalsRule 506(b)
▶$9KraisedApr 2025 · 29 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lori BirderDirector
- Michael ChancellorExecutive Officer, Director
- Ryan PruchnicDirector
- Jonathan KaufmanExecutive Officer, Director
- Daniel CohenDirector
- Byong KimDirector
- Douglas JohnstonExecutive Officer
- Naoki YoshimuraDirector
- Offering amount
- $9K
- Amount sold
- $9K
- Sales commissions
- $1.1M
- Placement agents
- Eric P. Meyer
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.6MraisedJan 2025 · 26 investors · PharmaceuticalsRule 506(b)
▶$2.6MraisedJan 2025 · 26 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lori BirderDirector
- Jonathan KaufmanExecutive Officer, Director
- Byong KimDirector
- Douglas JohnstonExecutive Officer
- Michael ChancellorExecutive Officer, Director
- Daniel CohenDirector
- Ryan PruchnicDirector
- Naoki YoshimuraDirector
- Offering amount
- $6M
- Amount sold
- $2.6M
- Minimum investment
- $50K
- Sales commissions
- $441.6K
- Placement agents
- Eric P. Meyer
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$120.1KraisedAug 2024 · 1 investors · PharmaceuticalsRule 506(b)
▶$120.1KraisedAug 2024 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Douglas JohnstonExecutive Officer
- Michael ChancellorExecutive Officer, Director
- Lori BirderDirector
- Daniel CohenDirector
- Naoki YoshimuraDirector
- Jonathan KaufmanExecutive Officer, Director
- Ryan PruchnicDirector
- Byong KimDirector
- Offering amount
- $120.1K
- Amount sold
- $120.1K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedNov 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$2MraisedNov 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Douglas JohnstonExecutive Officer
- Lori BirderDirector
- Ryan PruchnicDirector
- Byong KimDirector
- Jonathan KaufmanExecutive Officer, Director
- Naoki YoshimuraDirector
- Daniel CohenDirector
- Michael ChancellorExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- Sales commissions
- $150K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$122.4KofferedSep 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$122.4KofferedSep 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Douglas JohnstonExecutive Officer
- Michael ChancellorExecutive Officer, Director
- Naoki YoshimuraDirector
- Lori BirderDirector
- Jonathan KaufmanExecutive Officer, Director
- Ryan PruchnicDirector
- Daniel CohenDirector
- Byong KimDirector
- Offering amount
- $122.4K
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.1MraisedMay 2021 · 43 investors · PharmaceuticalsRule 506(b)
▶$3.1MraisedMay 2021 · 43 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- JONATHAN KAUFMANExecutive Officer, Director
- THOMAS PETZINGER, JR.Director
- MICHAEL CHANCELLORDirector
- DAVID BATTLEMANDirector
- Offering amount
- $3.6M
- Amount sold
- $3.1M
- Minimum investment
- $25K
- Sales commissions
- $40.5K
- Placement agents
- SPARTAN CAPITAL SECURITIES, LLC
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Lipella Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Lipella Pharmaceuticals do?
- Lipella Pharmaceuticals was a clinical-stage biotechnology company that developed therapies using a proprietary liposomal drug delivery platform, advancing candidates such as LP-10 and LP-310 through FDA-authorized Phase 2 trials in indications including oral lichen planus and hemorrhagic cystitis. The company ceased research and development activities in 2026 after a court-approved sale of its drug programs and intellectual property to XRAIY LLC, and the site now serves as a historical corporate archive.
- Who founded Lipella Pharmaceuticals?
- Lipella Pharmaceuticals was founded by Michael Chancellor, Jonathan Kaufman.
- How much funding has Lipella Pharmaceuticals raised?
- Lipella Pharmaceuticals has disclosed $7.8M raised across 5 of its 6 known rounds.
- Where is Lipella Pharmaceuticals headquartered?
- Lipella Pharmaceuticals is headquartered in Pittsburgh, US.